循环肿瘤DNA在乳腺癌诊治中应用的研究

摘要/Abstract

中图分类号:

R737.9

金泽宇, 陈小松. 循环肿瘤DNA在乳腺癌诊治中应用的研究[J]. 外科理论与实践, 2018, 23(05): 473-476.

[1] De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer[J]. Mol Oncol,2016,10(3):464-474.
[2] 陈小松, 沈坤炜. 乳腺癌“液体活检”: 血清标志物与循环肿瘤细胞的检测[J]. 分子诊断与治疗杂志,2012,4(6):410-414.
[3] Mandel P, Metais P.Les acides nuleiques du plasma sanguin chez l’homme[J]. CRSeances Soc Biol Fil,1948, 142:241-243
[4] Leon SA, Shapiro B, Sklaroff DM, et al.Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res,1977,37(3):646-650.
[5] Stroun M, Anker P, Maurice P, et al.Neoplastic characteristcs of the DNA found in the plasma of cancer patients[J]. Oncology,1989,46(5):318-322.
[6] Thakur BK, Zhang H, Becker A, et al.Double-stranded DNA in exosomes: a novel biomarker in cancer detection[J]. Cell Res,2014,24(6):766-769.
[7] Siravegna G, Marsoni S, Siena S, et al.Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol,2017,14(9):531-548.
[8] 叶青, 江泽飞. 循环肿瘤DNA检测在乳腺癌诊断中的临床应用[J]. 中国癌症杂志,2016,26(11):947-951.
[9] Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al.Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors[J]. Clin Chem,2015,61(1):297-304.
[10] Watanabe M, Kawaguchi T, Isa S, et al.Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR[J]. Clin Cancer Res,2015,21(15):3552-3560.
[11] Zhu G, Ye X, Dong Z, et al.Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer[J]. J Mol Diagn,2015, 17(3):265-272.
[12] Sacher AG, Paweletz C, Dahlberg SE, et al.Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer[J]. JAMA Oncol,2016,2(8):1014-1022.
[13] Pekin D, Skhiri Y, Baret JC, et al.Quantitative and sensitive detection of rare mutations using droplet-based microfluidics[J]. Lab Chip,2011,11(13):2156-2166.
[14] Oshiro C, Kagara N, Naoi Y, et al.PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients[J]. Breast Cancer Res Treat,2015, 150(2):299-307.
[15] Leary RJ, Kinde I, Diehl F, et al. Development of perso-nalized tumor biomarkers using massively parallel sequencing[J]. Sci Transl Med,2010,2(20):20ra14.
[16] Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing[J]. Sci Transl Med,2012, 4(162):162ra154.
[17] Wang TL, Maierhofer C, Speicher MR, et al.Digital ka-ryotyping[J]. Proc Natl Acad Sci U S A,2002,99(25):16156-16161.
[18] Paweletz CP, Sacher AG, Raymond CK, et al.Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients[J]. Clin Cancer Res,2016,22(4):915-922.
[19] Shaw JA, Page K, Blighe K, et al.Genomic analysis of circulating cell-free DNA infers breast cancer dormancy[J]. Genome Res,2012,22(2):220-231.
[20] Murtaza M, Dawson SJ, Pogrebniak K, et al.Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer[J]. Nat Commun,2015,6:8760.
[21] Murtaza M, Dawson SJ, Tsui DW, et al.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA[J]. Nature,2013,497(7447):108-112.
[22] Guo S, Diep D, Plongthongkum N, et al.Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA[J]. Nat Genet,2017,49(4):635-642.
[23] Xu RH, Wei W, Krawczyk M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater,2017,16(11):1155-1161.
[24] Umetani N, Giuliano AE, Hiramatsu SH, et al.Prediction of breast tumor progression by integrity of free circulating DNA in serum[J]. J Clin Oncol,2006,24(26):4270-4276.
[25] Stoetzer OJ, Fersching DM, Salat C, et al.Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin[J]. Cancer Lett,2013,336(1):140-148.
[26] Beaver JA, Jelovac D, Balukrishna S, et al.Detection of cancer DNA in plasma of patients with early-stage breast cancer[J]. Clin Cancer Res,2014,20(10):2643-2650.
[27] Page K, Guttery DS, Fernandez-Garcia D, et al.Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer[J]. Clin Chem,2017,63(2):532-541.
[28] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med,2014,6(224):224ra24.
[29] Madhavan D, Wallwiener M, Bents K, et al.Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat,2014,146(1):163-174.
[30] Olsson E, Winter C, George A, et al.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease[J]. EMBO Mol Med,2015,7(8):1034-1047.
[31] Dawson SJ, Tsui DW, Murtaza M, et al.Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med,2013,368(13):1199-1209.
[32] Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer[J]. Sci Transl Med,2015,7(302):302ra133.
[33] Takahashi H, Kagara N, Tanei T, et al. Correlation of methylated circulating tumor DNA with response to neoadjuvant chemotherapy in breast cancer patients[J]. Clin Breast Cancer,2017,17(1):61-69.e3.
[34] Riva F, Bidard FC, Houy A, et al.Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer[J]. Clin Chem,2017,63(3):691-699.
[35] Guttery DS, Page K, Hills A, et al.Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer[J]. Clin Chem,2015,61(7):974-982.
[36] Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer[J]. Sci Transl Med,2015,7(313):313ra182.
[37] Gevensleben H, Garcia-Murillas I, Graeser MK, et al.Noninvasive detection of HER2 amplification with plasma DNA digital PCR[J]. Clin Cancer Res,2013,19(12):3276-3284.
[38] Bechmann T, Andersen RF, Pallisgaard N, et al.Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer[J]. J Cancer Res Clin Oncol,2013,139(6):995-1003.
[39] Appierto V, Di Cosimo S, Reduzzi C, et al.How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case[J]. Semin Cancer Biol,2017,44:106-116.

循环肿瘤DNA在乳腺癌诊治中应用的研究

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价

[1]	张小丽　李赞　宋达疆　王业成　海涛.带蒂胸外侧动脉穿支皮瓣在保乳术后即刻乳房重建中的临床应用[J]. 组织工程与重建外科杂志, 2022, 18(5): 382-.
[2]	宋达疆　李赞　章一新.带蒂腹直肌皮瓣联合游离腹壁下动脉穿支皮瓣移植重建胸壁巨大缺损的手术策略[J]. 组织工程与重建外科杂志, 2022, 18(5): 386-.
[3]	姚成才　陈明　刘长春　黄传蔷　冼家仪　严国标　陈庞洲.硅凝胶乳房假体联合钛网补片在早期乳腺癌即刻乳房重建中的应用[J]. 组织工程与重建外科杂志, 2022, 18(3): 247-.
[4]	廖晓明　蒋奕　唐玮　杨华伟　姬逸男　韦莉颖.薄层血管化腹股沟淋巴结皮瓣移植联合反向淋巴显影在继发性上肢淋巴水肿手术中的应用[J]. 组织工程与重建外科杂志, 2022, 18(1): 8-.
[5]	宋景涌汤鹏钟晓捷刘侠孙洋亢玉王遥佳陈安玥陈怡安吉训通周艳虹蒋曼妃修骋穆籣.吻合口通畅性量化分析应用于乳腺癌腋窝淋巴结清扫术同期预防性淋巴管静脉吻合1例[J]. 组织工程与重建外科杂志, 2022, 18(1): 34-.
[6]	陈小松, 沈坤炜, 李宏为.早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022, 27(05): 385-386.
[7]	吴佳毅, 陆裕杰, 何金光, 沈坤炜, 徐华.乳腺癌术后植入物乳房重建技术[J]. 外科理论与实践, 2022, 27(05): 387-391.
[8]	陈益定, 吴世杰.遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395.
[9]	谢妍妍, 吕青, 杜正贵.乳腺腔镜和机器人手术的现状及未来之路——华西医院经验分享[J]. 外科理论与实践, 2022, 27(05): 396-402.
[10]	周文斌, 唐新宇, 王水.局部微波消融技术在乳腺癌治疗中的应用[J]. 外科理论与实践, 2022, 27(05): 403-405.
[11]	曹璐, 郑思悦, 陈佳艺.早期乳腺癌区域淋巴结局部处理[J]. 外科理论与实践, 2022, 27(05): 406-410.
[12]	黄蔚, 李恒宇, 丁晓毅.晚期乳腺癌介入诊疗的价值及应用[J]. 外科理论与实践, 2022, 27(05): 411-415.
[13]	舒兰, 陈小松.ER⁺/HER2^-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2022, 27(05): 416-420.
[14]	杨崔燕, 王豪雨, 陈小松, 沈坤炜.抑癌基因TP53突变状态与三阴性乳腺癌病人预后的研究[J]. 外科理论与实践, 2022, 27(05): 421-428.
[15]	潘睿忻综述, 陈小松, 沈坤炜审校.循环肿瘤DNA和循环肿瘤细胞检测乳腺癌微小残留病灶的研究[J]. 外科理论与实践, 2022, 27(05): 463-467.